Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03341078 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
NCT03341078: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT03341078 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 176 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03341078, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
Study Summary
Addiction to methamphetamine is a serious health problem in the United States. Right now, there are no medications that a doctor can give someone to help them stop using methamphetamine. More research is needed to develop drugs for methamphetamine addiction. Ibudilast (the study drug) is a drug that could help people addicted to methamphetamine.
Interventions
- DRUG Placebo Oral Tablet
- DRUG Ibudilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2025-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03341078
The ClinicalTrials.gov registry entry for NCT03341078 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03341078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03341078 about?
NCT03341078 is a clinical study titled "Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users". Addiction to methamphetamine is a serious health problem in the United States. Right now, there are no medications that a doctor can give someone to help them stop using methamphetamine. More research is needed to develop drugs for methamphetamine addiction. Ibudilast (the study drug) is a drug that...
What is the current status of trial NCT03341078?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2019-05-01. Estimated completion is 2025-10-15.
What interventions are being tested in trial NCT03341078?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Ibudilast (DRUG).
Who is sponsoring clinical trial NCT03341078?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.